Literature DB >> 16757567

Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Mark P Rubinstein1, Marek Kovar, Jared F Purton, Jae-Ho Cho, Onur Boyman, Charles D Surh, Jonathan Sprent.   

Abstract

IL-15 is normally presented in vivo as a cell-associated cytokine bound to IL-15Ralpha. We show here that the biological activity of soluble IL-15 is much improved after interaction with recombinant soluble IL-15Ralpha; after injection, soluble IL-15/IL-15Ralpha complexes rapidly induce strong and selective expansion of memory-phenotype CD8(+) cells and natural killer cells. These findings imply that binding of IL-15Ralpha to IL-15 may create a conformational change that potentiates IL-15 recognition by the betagamma(c) receptor on T cells. The enhancing effect of IL-15Ralpha binding may explain why IL-15 normally functions as a cell-associated cytokine. Significantly, the results with IL-2, a soluble cytokine, are quite different; thus, IL-2 function is markedly inhibited by binding to soluble IL-2Ralpha.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757567      PMCID: PMC1482584          DOI: 10.1073/pnas.0600240103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  Interleukin 15: biology and relevance to human disease.

Authors:  T A Fehniger; M A Caligiuri
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

2.  Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2.

Authors:  H Kobayashi; Y Tagaya; E S Han; I S Kim; N Le; C H Paik; I Pastan; D L Nelson; T A Waldmann; J A Carrasquillo
Journal:  Cytokine       Date:  1999-12       Impact factor: 3.861

3.  The Sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo.

Authors:  M Orchardson; J A Gracie; B P Leung; H Guan; W Niedbala; G K Paterson; I B McInnes; F Y Liew
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

4.  IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation.

Authors:  F Mattei; G Schiavoni; F Belardelli; D F Tough
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

Review 5.  The IL-2/IL-15 receptor systems: targets for immunotherapy.

Authors:  Thomas A Waldmann
Journal:  J Clin Immunol       Date:  2002-03       Impact factor: 8.317

6.  Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells.

Authors:  Adam D Judge; Xiaohong Zhang; Hideki Fujii; Charles D Surh; Jonathan Sprent
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

7.  Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.

Authors:  M K Kennedy; M Glaccum; S N Brown; E A Butz; J L Viney; M Embers; N Matsuki; K Charrier; L Sedger; C R Willis; K Brasel; P J Morrissey; K Stocking; J C Schuh; S Joyce; J J Peschon
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

8.  Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells.

Authors:  Todd C Becker; E John Wherry; David Boone; Kaja Murali-Krishna; Rustom Antia; Averil Ma; Rafi Ahmed
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

9.  Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells.

Authors:  William C Kieper; Joyce T Tan; Brea Bondi-Boyd; Laurent Gapin; Jonathan Sprent; Rhodri Ceredig; Charles D Surh
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

10.  T cell-independent interleukin 15Ralpha signals are required for bystander proliferation.

Authors:  J P Lodolce; P R Burkett; D L Boone; M Chien; A Ma
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307

View more
  193 in total

Review 1.  Once a killer, always a killer: from cytotoxic T cell to memory cell.

Authors:  Leo Lefrançois; Joshua J Obar
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  STAT5 is critical to maintain effector CD8+ T cell responses.

Authors:  Pulak Tripathi; Sema Kurtulus; Sara Wojciechowski; Allyson Sholl; Kasper Hoebe; Suzanne C Morris; Fred D Finkelman; H Leighton Grimes; David A Hildeman
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

3.  The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Authors:  Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

Review 4.  Superagonism at G protein-coupled receptors and beyond.

Authors:  R Schrage; A De Min; K Hochheiser; E Kostenis; K Mohr
Journal:  Br J Pharmacol       Date:  2015-10-24       Impact factor: 8.739

5.  IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.

Authors:  Yin Guo; Liming Luan; Whitney Rabacal; Julia K Bohannon; Benjamin A Fensterheim; Antonio Hernandez; Edward R Sherwood
Journal:  J Immunol       Date:  2015-07-27       Impact factor: 5.422

6.  Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques.

Authors:  Maren Q DeGottardi; Afam A Okoye; Mukta Vaidya; Aarthi Talla; Audrie L Konfe; Matthew D Reyes; Joseph A Clock; Derick M Duell; Alfred W Legasse; Amit Sabnis; Byung S Park; Michael K Axthelm; Jacob D Estes; Keith A Reiman; Rafick-Pierre Sekaly; Louis J Picker
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

7.  IL-2 complex treatment can protect naive mice from bacterial and viral infection.

Authors:  Sara E Hamilton; Jason M Schenkel; Adovi D Akue; Stephen C Jameson
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

8.  Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.

Authors:  Clémentine Perrier; Ingrid Arijs; Dominiek Staelens; Christine Breynaert; Isabelle Cleynen; Kris Covens; Marc Ferrante; Gert Van Assche; Séverine Vermeire; Gert de Hertogh; Frans Schuit; Paul Rutgeerts; Jan L Ceuppens
Journal:  Immunology       Date:  2013-01       Impact factor: 7.397

9.  IL-15 Agonists: The Cancer Cure Cytokine.

Authors:  Jennifer Wu
Journal:  J Mol Genet Med       Date:  2013-10-28

10.  Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.

Authors:  Jason C Steel; Charmaine A Ramlogan; Ping Yu; Yoshio Sakai; Guido Forni; Thomas A Waldmann; John C Morris
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.